

Cite this: *Mater. Adv.*, 2023,  
4, 5291

# Detection of specific antibodies against SARS-CoV-2 spike protein *via* ultra-sensitive bio-functionalized carbonnitride-reduced graphene oxide electrochemical immunosensing platform in real samples†

Mohd. Abubakar Sadique,<sup>a</sup> Shalu Yadav,<sup>ab</sup> Pushpesh Ranjan,<sup>ab</sup>  
Raghuraj Singh Chouhan,<sup>b</sup>\* Ivan Jerman,<sup>d</sup> Ashok Kumar,<sup>e</sup> Saurabh Saigal,<sup>e</sup>  
Sagar Khadanga,<sup>e</sup> Raju Khan<sup>b</sup>\*<sup>ab</sup> and Avanish K. Srivastava<sup>a</sup>

In this work, we fabricate a facile *de novo* synthesis route to prepare bio-functionalized carbon nitride-reduced graphene oxide with chitosan (Chi) nanocomposite (C<sub>3</sub>N<sub>4</sub>/RGO/Chi). The nitrogen-rich C<sub>3</sub>N<sub>4</sub> has been synthesized through facile and low-cost thermal oxidation and offers a metal-free and highly active surface for synergistic modification with RGO and Chi. Moreover, the synergistically incorporated C<sub>3</sub>N<sub>4</sub>/RGO and biopolymer improve the electrocatalytic activity, provide surface functionalities, and enhance electroconductivity for immunosensing applications. Consequently, the bio-functionalized C<sub>3</sub>N<sub>4</sub>/RGO nanocomposite provides a suitable substrate for the immobilization of SARS-CoV-2 RBD spike protein. The immunosensor detects SARS-CoV-2 antibodies in a wide detection range from 10 zg mL<sup>-1</sup> (10 × 10<sup>-21</sup> g mL<sup>-1</sup>) to 100 ng mL<sup>-1</sup> with an ultra-low detection limit (LOD) of 3.31 zg mL<sup>-1</sup>. The validation of the immunosensor was also carried out on spiked serum samples, which show a linear detection range of 100 ag mL<sup>-1</sup> to 100 ng mL<sup>-1</sup> and a LOD of 1.73 ag mL<sup>-1</sup>. Nevertheless, the clinical diagnostic application of the immunosensor is validated through the examination of real serum samples from COVID-19 patients. The results suggest that the immunosensor can be efficiently used as a screening platform to distinguish between positive and negative samples with high accuracy. The findings of the work have the potential to translate the immunosensing strategy into next-generation point-of-care testing (POCT) of various infectious diseases.

Received 12th July 2023,  
Accepted 3rd October 2023

DOI: 10.1039/d3ma00399j

rsc.li/materials-advances

## Introduction

The global pandemic of coronavirus 2019 (COVID-19) has been shrinking and re-emerging randomly in the last two years with mutations in the variants of the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2).<sup>1</sup> The concerning situation had increased the number of cases due to a poor understanding of the SARS-CoV-2, inadequate detection techniques, and weak

vaccination efficacy.<sup>2-4</sup> Standard diagnostic techniques like reverse transcription polymerase chain reaction (RT-PCR), enzyme-linked immunosorbent assay (ELISA), clustered regularly interspaced short palindromic repeats (CRISPR), *etc.* have been extensively utilized for primarily testing and screening of COVID-19.<sup>5,6</sup> Even after significant modifications in conventional diagnostic techniques as per modern requirements, they still lack the potential to accomplish the growing demands of disease monitoring.<sup>7,8</sup> The boom in cases has drawn attention to the hunt for alternative measures to diagnose COVID-19. In the last two years, the advancements in material science and nanotechnology have shifted the diagnostic developments in the regime of biosensors with the use of materials having better sensitivity and stability.<sup>9,10</sup> Various biosensors like optical,<sup>11,12</sup> lateral flow,<sup>13</sup> thermoelectric,<sup>14</sup> piezoelectric,<sup>15</sup> field-effect transistor,<sup>16</sup> electrochemical,<sup>17</sup> colorimetric,<sup>18</sup> and mass-based<sup>19</sup> have been explored for the detection capabilities of the SARS-CoV-2 virus.<sup>20</sup> Among these, few have the potential to be translated from lab scale to point-of-care testing

<sup>a</sup> CSIR-Advanced Materials and Processes Research Institute (AMPRI), Hoshangabad Road, Bhopal-462026, India. E-mail: khan.raju@gmail.com

<sup>b</sup> Academy of Scientific and Innovative Research (AcSIR), Ghaziabad-201002, India

<sup>c</sup> Jožef Stefan Institute, Jamova Cesta-39, Ljubljana-1000, Slovenia.

E-mail: raghuraj.singh@ijs.si

<sup>d</sup> National Institute of Chemistry, Hajdrihova 19, Ljubljana-1000, Slovenia

<sup>e</sup> All India Institute of Medical Sciences (AIIMS), Bhopal-462020, India

† Electronic supplementary information (ESI) available: Experimental section, synthesis of GO, nanomaterial characterization (AFM, XPS, SEM), scan rate studies. See DOI: <https://doi.org/10.1039/d3ma00399j>





Herein, after considering all the aforesaid particulars, we designed an ultrasensitive immunosensing platform for the detection of antibodies specific to SARS-CoV-2 spike antigen based on bio-functionalized  $C_3N_4$ /RGO nanocomposite for the first time as per the literature. The fabricated immunosensor exhibits various merits which include facile synthesis steps, rapid and accurate analysis, selective, reproducible, and stable immunosensing platform. The obtained results affirm the ultrasensitive detection limit of the immunosensor is  $3.31 \text{ zg mL}^{-1}$ . The immunosensor has a LOD of  $1.73 \text{ ag mL}^{-1}$  in serum samples and can even distinguish between positive and negative real patient samples with 100% accuracy. On that account, this work paves the way for its translation into miniaturized portable devices for POCT of COVID-19 patients and further for other infectious diseases as well.

## Experimental details

### Materials and solvents

Recombinant SARS-CoV-2 Spike RBD His-tag protein (Cat # 10500-CV-100), and the SARS-CoV-2 Spike RBD antibody (Cat # MAB10540-100 SARS-CoV-2 antibodies) were purchased from R&D Systems (United States). Graphite powder, dicyandiamide, *N*-(3-dimethyl aminopropyl)-*N'*-ethyl carbodiimide hydrochloride (EDC), *N*-hydroxysulfosuccinimide sodium (NHS), and bovine serum albumin (BSA) was purchased from Sigma Aldrich, USA. Chitosan (Chi) (low molecular weight), and Hydrogen peroxide ( $H_2O_2$ ; ~30%) were purchased from Central Drug House (P) Ltd (CDH), India. Sulfuric acid ( $H_2SO_4$ ), orthophosphoric acid ( $H_3PO_4$ ), and hydrochloric acid (HCl) were purchased from RANKEM, India. Potassium hydroxide (KOH), isopropyl alcohol (IPA), Potassium permanganate ( $KMnO_4$ ), potassium ferricyanide(III) ( $K_3[Fe(CN)_6]$ ), potassium ferrocyanide trihydrate ( $K_4[Fe(CN)_6] \cdot 3H_2O$ ), sodium dihydrogen phosphate 2-hydrate ( $NaH_2PO_4 \cdot 2H_2O$ ), disodium hydrogen phosphate ( $Na_2HPO_4$ ), and potassium chloride (KCl), were procured from SRL Chemical, India. Glacial acetic acid and sodium hydroxide (NaOH pellets) were purchased from Merck, India. All solutions were prepared in ultrapure water from a Merck Milli-Q instrument. Milli-Q water (18.2  $\Omega$  cm) was used throughout the experiment.

### Instrumentations

For optical characterization, crystallinity, roughness, binding energy, vibrational bonding, molecular states, and morphology of the synthesized nanomaterials; UV-visible spectroscopy (Evolution 220 UV-vis spectrophotometer, Thermo Fisher Scientific), X-ray diffraction (Rigaku Miniflex-1; Cu  $K\alpha$  radiation,  $\lambda = 1.54 \text{ \AA}$ ), atomic force microscopy (Witec alpha300 A-AFM microscope), X-ray photoelectron spectroscopy (targeted factor analysis, TFA (Physical Electronics)), Fourier-transform infrared spectroscopy (Bruker, Alpha-II), Raman Spectroscopy (IndiRAM- CTR 300, Technos Instruments), Scanning electron microscopy (JEOL, JCM-6000PLUS & JED-2300, Analysis Station) were used respectively. For the electrochemical characterization and detection, electrochemical workstation (Autolab P/G electrochemical analyzer; Metrohm, PGSTAT204) was employed.

### Synthesis and preparation of $C_3N_4$ nanosheets

The  $C_3N_4$  nanosheet powder was synthesized by thermal oxidation of a dicyandiamide monomer as reported by Singh *et al.* with minor modifications.<sup>52</sup> Briefly, 5 g dicyandiamide was dried and preheated in an oven for 2 h at  $600 \text{ }^\circ\text{C}$ . The product was cooled at ambient temperature, which was then ground into fine powder. The obtained 3 g powder was again heated at a rate of  $5 \text{ }^\circ\text{C min}^{-1}$  and kept at  $550 \text{ }^\circ\text{C}$  for 2 h in a ceramic boat. A 2.6 g of yellowish color powder was obtained which was collected as  $C_3N_4$  nanosheets. This approach is simple, green, and has a high yield.

### Synthesis of $C_3N_4$ /RGO nanocomposite

The GO was prepared by the Tour's method,<sup>53</sup> the synthesis steps in detail are given in supplementary information. The GO was reduced to RGO using ethanol in an alkaline medium (pH adjusted by KOH) by keeping it in an oven at  $80 \text{ }^\circ\text{C}$  for 2 hours. Next, the synthesized  $C_3N_4$  was dispersed in isopropanol and sonicated to make a solution. Further,  $C_3N_4$ /RGO nanocomposites were prepared by mixing 500  $\mu\text{L}$  RGO ( $0.15 \text{ mg mL}^{-1}$ ) suspension with 300  $\mu\text{L}$   $C_3N_4$  ( $0.6 \text{ mg mL}^{-1}$ ) solution. The mixture was sonicated for 30 min for thorough mixing.<sup>54</sup> The obtained  $C_3N_4$ /RGO was further air-dried and kept in a desiccator before further use.

### Synthesis of bio-functionalized $C_3N_4$ /RGO nanocomposite

The bio-functionalized  $C_3N_4$ /RGO was prepared through one-step mixing of  $C_3N_4$ /RGO with the Chi as shown in Scheme 1. For this,  $1 \text{ mg mL}^{-1}$  of  $C_3N_4$ /RGO in Milli-Q water was sonicated for 10 min for homogeneous mixing. Subsequently, 300  $\mu\text{L}$  of glacial acetic acid was added while stirring, and then 20 mg of Chi was mixed under constant stirring. The above solution was further sonicated for 10 min to obtain a uniform bio-functionalized  $C_3N_4$ /RGO nanocomposite solution.<sup>55</sup>

### Electrochemical studies

The electrochemical analysis of the synthesized nanomaterials has been done on a three-electrode electrochemical workstation. Here, the Ag/AgCl reference electrode and Pt wire counter electrode were used along with a nanomaterials-modified glassy carbon electrode (GCE) as the working electrode. The techniques such as cyclic voltammetry (CV), and differential pulse voltammetry (DPV) were carried out in the potential window of  $-0.3$  to  $+0.8 \text{ V}$ , and electrochemical impedance spectroscopy (EIS) in the frequency range of 0.1 Hz to 0.1 MHz. The electrode rinsing buffer was made up of 0.1 M PBS (pH 7) and 0.1 M KCl. The 0.1 M PBS comprising 5 mM ferricyanide/ferrocyanide redox couple and 0.1 M KCl of pH 7.4 is used as PBS for electrochemical characterizations and detection purposes. All the optimization and detection studies were done with triplicate repetition.

### SARS-CoV-2 sample preparation

The initial performance analysis of the fabricated immunosensors was carried out in PBS (pH 7.4) solution. SARS-CoV-2 spike





**Scheme 1** (A) Illustration of the steps involved in the synthesis of  $C_3N_4$ /RGO/Chi nanocomposite and (B) fabrication of the immunosensor for the detection of SARS-CoV-2 spike antibodies.

antibodies detection samples were prepared in PBS (pH 7.4) solution and spiked in diluted serum samples. The synthetic SARS-CoV-2 spike antibodies detection samples (100 ng to 10 zg) were prepared from the  $5 \mu\text{g mL}^{-1}$  stock solution of SARS-CoV-2 spike antibodies (Cat# MAB10540-100; diluted from 100  $\mu\text{g}$ ) in the PBS (pH 7.4) solution by serial dilution from concentrations of 10 zg  $\text{mL}^{-1}$  to 100 ng  $\text{mL}^{-1}$ . In brief, the initial antibody concentration in the stock solution is 100  $\mu\text{g mL}^{-1}$ . To create a 1 mL solution with a final concentration of 10  $\mu\text{g mL}^{-1}$ , add 100  $\mu\text{L}$  to 900  $\mu\text{L}$  of diluent, achieving a 1 : 9 dilution. Repeat this process to achieve the final solution concentration of 10 zg  $\text{mL}^{-1}$ . For the spiked serum samples, human serum was diluted in a 1 : 10 ratio in PBS, and then different concentrations of SARS-CoV-2 spike antibodies ranging from 100 ag  $\text{mL}^{-1}$  to 100 ng  $\text{mL}^{-1}$  were made by serial dilution. Further, for the validation of immunosensor performance, the real patient serum samples ( $N = 20$ , 10 +ve (P1–P10), 10 –ve (N1–N10)) were received from AIIMS, Bhopal. Approval of the Institutional Human Ethics Committee of AIIMS, Bhopal, and the Institutional Biosafety Committee of CSIR-AMPRI, Bhopal were obtained. Blood samples were collected with written informed consent. The real patient samples were diluted in a 1 : 10 ratio in PBS (pH 7.4) for detection. All the samples were kept at  $-20^\circ\text{C}$  in a deep freezer before further use.

### Fabrication of SARS-CoV-2 immunosensor

The synthesized nanocomposite was used for several steps of modification of the GCE for the fabrication of the immunosensor. At first, 4  $\mu\text{L}$  of  $C_3N_4$ /RGO/Chi nanocomposite was drop cast on a 3 mm diameter of the GCE and left for drying at ambient temperature for 24 h. Afterward, 5  $\mu\text{L}$  of *N*-(3-dimethyl amino-propyl)-*N'*-ethyl carbodiimide hydrochloride, *N*-hydroxysulfosuccinimide sodium, (EDC: NHS) (4 : 1) was drop cast on the

nanocomposite as an amide cross-linker for 1.5 h. The Milli-Q water was used to wash the excess cross-linker. Then 5  $\mu\text{L}$  of  $5 \mu\text{g mL}^{-1}$  SARS-CoV-2 spike antigen (Cat # 10500-CV-100; diluted from 100  $\mu\text{g}$  stock solution) was immobilized and kept at  $4^\circ\text{C}$  overnight for incubation. Further, the unbound spike antigen was removed using a rinsing buffer. At last, 5  $\mu\text{L}$  of 1% bovine serum albumin (BSA) was used as a blocking agent of the reactive sites of the electrode to avoid unspecific binding, and excess BSA was removed with a rinsing buffer. The working electrodes were electrochemically characterized after each surface modification step. The  $C_3N_4$ /RGO/Chi/SARS-CoV-2 spike antigen/BSA is termed an immunosensor. The fabricated immunosensor is ready for the detection of SARS-CoV-2 spike antibodies and the steps involved in the fabrication of the immunosensor are depicted in Scheme 1.

## Results and discussion

### Optical characterization

In the UV-vis spectroscopy, the  $C_3N_4$ /RGO composite does not have any significant peak other than that of RGO at about 240 nm. Whereas the  $C_3N_4$ /RGO/Chi nanocomposite has a characteristic peak of  $C_3N_4$ /RGO at about 240 nm and an absorption peak of Chi at around 730 nm. The UV-vis spectra of the nanocomposites are shown in Fig. 1A. FTIR spectroscopy was used to characterize the functional groups, and bond strength of the nanomaterials with major emphasis on the presence of vibrational bonds. As shown in Fig. 1B, the base material  $C_3N_4$  consists of an N–H bond stretching at a  $3152 \text{ cm}^{-1}$  vibrational band. For the C=N group, the vibrational stretching bands have peaks appearing at 1229, 1314, 1394, and  $1453 \text{ cm}^{-1}$ . However, the C–N bond has a stretching band at 1535 and  $1628 \text{ cm}^{-1}$ . A sharp peak is visible at  $804 \text{ cm}^{-1}$  for out-of-plane bending of the tri-s-triazine allotrope of  $C_3N_4$ .<sup>52</sup>






Fig. 1 (A) UV-vis spectra of  $C_3N_4$ /RGO, and  $C_3N_4$ /RGO/Chi nanocomposite (B) FTIR spectra of  $C_3N_4$ , RGO, Chi, and  $C_3N_4$ /RGO/Chi nanocomposite, (C) XRD patterns of  $C_3N_4$ ,  $C_3N_4$ /RGO, and  $C_3N_4$ /RGO/Chi nanocomposite, and (D) Raman spectra of GO,  $C_3N_4$ /RGO, and  $C_3N_4$ /RGO/Chi nanocomposite.

The FTIR spectra of  $C_3N_4$  suggest the presence of primary and secondary amines. Further, the FTIR spectra of RGO have significant peaks for the stretching vibrational bands of the  $-OH$ ,  $C-H$  ( $sp^3$ ),  $C=O$ , and  $C=C$  bond at  $3371$ ,  $2923$ ,  $1706$ , and  $1544$   $cm^{-1}$  respectively.<sup>56–58</sup> The bending vibrations of  $C-OH$ ,  $C-H$ ,  $C-O-C$ , and  $C-O$  bonds are observed at  $1375$ ,  $1459$ ,  $1162$ , and  $1034$   $cm^{-1}$  respectively suggesting the successful reduction of GO.<sup>59</sup> In Chi, the stretching vibrational of  $-NH$ ,  $-NH_2$ ,  $C-H$ , and  $C-O$  groups is observed at  $3289$ ,  $1558$ ,  $1373$ , and  $1057$   $cm^{-1}$  respectively.<sup>60</sup> The polysaccharide structure of Chi has vibrational bands at  $895$  and  $1149$   $cm^{-1}$ .<sup>61</sup> Subsequently, the presence of all the characteristic peaks at  $802$ ,  $1012$ ,  $1147$ ,  $1402$ ,  $1544$ ,  $1630$ ,  $2909$ , and  $3229$   $cm^{-1}$  implies the coexistence of  $C_3N_4$ , RGO, and Chi in the  $C_3N_4$ /RGO/Chi nanocomposite.

#### Crystallinity characterization: X-ray diffraction spectroscopy

For the analysis of the crystallinity of the synthesized nanomaterials, XRD was done. The base nanomaterial  $C_3N_4$  has a distinctive crystalline peak at  $13.08^\circ$  and  $27.37^\circ$  and RGO has a broad peak at  $24.28^\circ$ . Fig. 1C shows the (100) and (002) plane of  $C_3N_4$  corresponding to tri-s-triazine units and conjugated aromatic system indicating the formation of the layered structure. In  $C_3N_4$ /RGO the (002) plane of both  $C_3N_4$  and RGO is seen which suggests stable hybridization of both two-dimensional nanomaterials in the form of  $C_3N_4$ /RGO nanosheets.<sup>54</sup> In the case of the  $C_3N_4$ /RGO/Chi nanocomposite, the characteristic peak of  $C_3N_4$  has diminished due to the coated surface by Chi.

The Chi covering in the  $C_3N_4$ /RGO/Chi nanocomposite is well seen in SEM images as well.<sup>55</sup>

#### Vibrational analysis: Raman spectroscopy

For the analysis of carbon-based nanocomposites, Raman spectroscopy is an effective tool for measuring the D, G, and 2D band peaks in terms of Raman shift. The disorder in  $sp^2$  carbon nanomaterials is observed in the Raman analysis. GO exhibited the D and G bands at  $1351$   $cm^{-1}$  and  $1588$   $cm^{-1}$ , respectively. On adding  $C_3N_4$  nanosheets, the shift in the D and G band peaks at  $1350$ , and  $1563$   $cm^{-1}$ , and the presence of a 2D band at  $2690$   $cm^{-1}$  evidenced a high reduction of GO to RGO and covalent binding of  $C_3N_4$  with RGO Fig. 1D. The difference in D and G band intensities and the presence of a 2D band at  $2690$   $cm^{-1}$  in  $C_3N_4$ /RGO suggests the highly conducting nature of the nanocomposite after the reduction of GO.<sup>62</sup> The C-NH bending region lies around  $1290$ – $1350$   $cm^{-1}$  and amide-I around  $1635$   $cm^{-1}$ .<sup>63</sup> The paranoic ring containing the methylene group in Chi has C-H stretching vibrations at around  $2885$ – $2945$   $cm^{-1}$ .<sup>64</sup> After the addition of Chi, the peak shifts in D, and G bands at  $1343$  and  $1603$   $cm^{-1}$  respectively, and the presence of broad 2D peaks around  $2937$   $cm^{-1}$  suggest the successful formation of Chi-covered  $C_3N_4$ /RGO nanocomposite.

After Raman characterization of the synthesized bio-functionalized  $C_3N_4$ /RGO nanocomposite, Raman mapping was carried out to evaluate the nanomaterial distribution on the surface and the arrangement of laminar structures of  $C_3N_4$  and






Fig. 2 (A) Optical image bio-functionalized  $C_3N_4$ /RGO nanocomposite on silica substrate at  $100\times$  magnification, (B) Raman spectra of bio-functionalized  $C_3N_4$ /RGO nanocomposite on a silica substrate, (C) Raman mapping image of the bio-functionalized  $C_3N_4$ /RGO nanocomposite, 2D Raman mapping image of (D) Si, (E) Chi, (F)  $C_3N_4$ /RGO.

RGO along with the covering of Chi on  $C_3N_4$ /RGO nanocomposite. A larger region was mapped for the identification of  $C_3N_4$ , RGO, and Chi dispersion in nanomaterials. The confocal Raman maps were created by raster scanning spectra at intervals of  $0.1\ \mu\text{m}$  throughout a specific region. The spectra collected can be plotted to identify the peak strength and spatial distribution of nanocomposites. The Raman mapping data of bio-functionalized  $C_3N_4$ /RGO nanocomposite shown in Fig. 2 depicts the Chi-coated layered structure of  $C_3N_4$  and RGO nanomaterials. As seen from the optical image (Fig. 2(A)), Raman spectra (Fig. 2(B)), and mapping image (Fig. 2(C)), it is clear that the synthesized bio-functionalized  $C_3N_4$ /RGO nanocomposite has uniformly distributed  $C_3N_4$ /RGO sheets which are decorated by Chi on the surface. The 2D Raman mapping image in Fig. 2(D–F) shows the distribution of Si/SiO<sub>2</sub>, Chi, and  $C_3N_4$ /RGO nanocomposite during Raman mapping.

### Morphological studies of the nanocomposites

The morphological characterization of synthesized nanomaterials was carried out using SEM. The SEM image of  $C_3N_4$  nanosheets is shown in Fig. S3 (ESI<sup>†</sup>). The morphology of  $C_3N_4$ /RGO was observed to be flaky sheets as seen in Fig. 3(A and B). A large number of nanocomposite bundles show the bulky nature of the nanocomposite that acts as a suitable substrate comprising abundant functional groups.<sup>65</sup> In the case of bio-functionalized  $C_3N_4$ /RGO nanocomposite the surface morphology of the nanocomposite reveals that Chi has covered  $C_3N_4$ /RGO making it more stable (Fig. 3(D, E)). The presence of Chi on the surface of  $C_3N_4$ /RGO facilitates its film-forming capabilities.<sup>66</sup> The EDX plot of  $C_3N_4$ /RGO (Fig. 3(C)) and  $C_3N_4$ /RGO/Chi (Fig. 3(F)) clearly distinguishes the presence of characteristic elements in the nanocomposites.

## Electrochemical studies

### Electrochemical characterizations

The electrochemical performance of the synthesized nanomaterials was analyzed by CV, DPV, and EIS techniques. As seen in

Fig. 4A, the CV characterization of the  $C_3N_4$  had an anodic peak current of  $44\ \mu\text{A}$ . On further modification with RGO, the increase in anodic peak current to  $54\ \mu\text{A}$  was observed due to the restoration of  $\pi$  electrons that facilitate electron transfer on the surface of RGO. Furthermore, the film-forming capacity and stability of the nanocomposite were improved by adding Chi which also electrocatalytic effect on the final nanocomposite having the anodic peak current of  $61\ \mu\text{A}$ . The  $C_3N_4$ /RGO/Chi nanocomposite has a maximum peak current of  $61\ \mu\text{A}$  which was slightly reduced to  $41\ \mu\text{A}$  after the immobilization of SARS-CoV-2 spike antigen due to the bilayer formation. Finally, after blocking with BSA, the current was further decreased to  $33\ \mu\text{A}$  suggesting the successful fabrication of the immunosensor. The binding of the SARS-CoV-2 spike antibodies was also analyzed which has the least current of  $28\ \mu\text{A}$  which suggests proper binding of the antibody–antigen complex. The comparative assessment of the modified electrodes was also carried out by the DPV technique (Fig. 4B) which shows a similar pattern as observed in CV peak current values for the modified electrodes. The change in peak current and peak potential after each modification step was due to the electrochemical characteristics of synthesized nanomaterials and their interaction with immobilized biomolecules that were visible in both CV and DPV curves.

The CV analysis was used to determine the effective surface area from the Randles–Sevcik equation. The peak current ( $I_p$ ) is expressed as:

$$I_p = (2.69 \times 10^5) \times (n)^{3/2} \times A \times (D)^{1/2} \times C \times (v)^{1/2} \quad (1)$$

where,  $n$  is the number of electrons transferred in the redox reaction (here,  $n = 1$ ),  $A$  is the effective active surface area of the electrode ( $\text{cm}^2$ ),  $D$  is the diffusion coefficient ( $D = 7.26 \times 10^{-6}\ \text{cm}^2\ \text{s}^{-1}$ ) for the ferri/ferrocyanide redox solution,  $C$  is the concentration of the ferri/ferrocyanide redox solution (here,  $5.0 \times 10^{-6}\ \text{mol}\ \text{cm}^{-3}$ ), and  $v$  is the scan rate (here,  $20.0\ \text{mV}\ \text{s}^{-1}$ ).

For the  $C_3N_4$ /RGO/Chi nanocomposite-modified electrode, the calculated effective surface area was  $12 \times 10^{-2}\ \text{cm}^2$ . This





Fig. 3 SEM images of (A) and (B)  $C_3N_4$ /RGO and (D) and (E) bio-functionalized  $C_3N_4$ /RGO nanocomposite. Elemental distribution of (C)  $C_3N_4$ /RGO and (F) bio-functionalized  $C_3N_4$ /RGO nanocomposite respectively.

proves the presence of a large effective surface area for the fabrication of the immunosensor. However, for the fabricated immunosensor the peak current observed was  $33 \mu A$ , which gave the effective surface area of the immunosensor to be  $6.53 \times 10^{-2} \text{ cm}^2$  for targeted binding of SARS-CoV-2 spike antigen-specific antibodies.

EIS studies were conducted to further study the electrochemical interfacial process of the modified electrode surfaces, and the Nyquist plots are displayed in Fig. 4(C). The interpretation of the EIS data may vary upon modification with nanocomposites or biological components. Subsequently, it is important to carefully understand the unique physical characteristics of each system before selecting the appropriate equivalent circuit model to represent the electrical effects of the electrochemical systems and to explain the mechanism of the reaction. The results presented here were fitted using an equivalent circuit model made up of a combination of resistors and capacitors to interpret the EIS results of nanocomposites, also considering the factors governing the electrochemical impedance on the biomolecules-modified surface.

The Nyquist plot in Fig. 4(C) illustrates each step of modification of the electrode surface, wherein the semi-circular segment is related to the charge-transfer resistance and the double-layer capacitance, and the linear segment is related to the diffusion-controlled during the redox processes at the electrode–electrolyte interface. The increase of the semicircle in the high-frequency region is due to the incorporation of biomolecules into the nanocomposite film ( $C_3N_4$ /RGO/Chi). To assess this effect, EIS data were fitted with the equivalent circuit model shown in Fig. S3 (ESI<sup>†</sup>). This equivalent circuit consists of a series resistance contribution ( $R_s$ ), which accounts for electrolyte and current collector resistance, and a charge-transfer resistance ( $R_{CT}$ ), which is associated with the interfacial faradaic process, and Warburg impedance ( $R_w$ ). The obtained  $R_{CT}$  of  $C_3N_4$  and  $C_3N_4$ /RGO was  $825 \Omega$ , and  $705 \Omega$  respectively. The

lower  $R_{CT}$  ( $46 \Omega$ ) of  $C_3N_4$ /RGO/Chi nanocomposite evidence that the  $C_3N_4$ /RGO/Chi nanocomposite sensing probe has superior electrochemical properties. Further on surface alteration with SARS-CoV-2 spike antigen, and blocking agent (BSA), the increase in  $R_{CT}$  values (from  $1581 \Omega$  to  $1862 \Omega$ ) is due to the steric hindrance in electron transfer from the addition of biological compounds on the surface which indicates successful fabrication of the immunosensor. The mechanism behind the extremely high electro-conductive nature is depicted in the Nyquist plot (Fig. 4(D)). The semicircular region at low frequencies projects towards the kinetic control mechanism that occurs at the electrode–electrolyte interface. On the other side, the linear line at a higher frequency region provides the diffusion-controlled mass transfer reaction at the electrode–electrolyte junction. The binding of an antibody–antigen complex is also proposed by the increased  $R_{CT}$  value of  $2352 \Omega$ .<sup>67</sup> The respective EIS fitting data is represented in Table 1.

The bode diagram provides a clear explanation of how the electrochemical system responds to changes in frequency and how this affects the dispersion of experimental data. The most practical method for extrapolating and analyzing impedance data at low frequencies is using the bode plot.<sup>68</sup> The correlation between the frequency and the shift in phase values and amplitude is shown in Fig. 4(E and F) respectively. The bode plot also decreased the dispersion of experimental results and clarified the electrochemical behavior of electrodes in low-frequency ranges (less than  $1000 \text{ Hz}$ ). The solution resistance corresponds to a plateau with a phase angle of  $0^\circ$  on the bode plot for the higher frequency area (more than  $1000 \text{ Hz}$ ). The classification of the median frequencies ( $1000\text{--}10 \text{ Hz}$ ) and the determination of the electrode's capacitive behavior, which specifies the dielectric characteristics of an electrically conductive electrode interface, were done using the rise in phase angles up to  $65^\circ$ . Mass transport processes, electron charge transfer phenomena, and





Fig. 4 Comparative electrochemical studies (A) CV, (B) DPV, (C) EIS, (D) graphical illustration of different mechanisms occurring in Nyquist plot, and (E) and (F) Bode plots of the modified working electrodes (i)  $\text{C}_3\text{N}_4$  nanosheets, (ii)  $\text{C}_3\text{N}_4/\text{RGO}$ , (iii)  $\text{C}_3\text{N}_4/\text{RGO}/\text{Chi}$  nanocomposite, (iv)  $\text{C}_3\text{N}_4/\text{RGO}/\text{Chi}/\text{SARS-CoV-2}$  spike antigen, (v)  $\text{C}_3\text{N}_4/\text{RGO}/\text{Chi}/\text{SARS-CoV-2}$  spike antigen/BSA, and (vi)  $\text{C}_3\text{N}_4/\text{RGO}/\text{Chi}/\text{SARS-CoV-2}$  spike antigen/BSA/SARS-CoV-2 spike antibodies in 0.1 M PBS (pH 7.4) containing 0.1 M KCl and 5 mM ferri/ferrocyanide redox solution.

Table 1 EIS Fitting data of each surface modification step of GCE

| Electrode  | $R_s$ ( $\Omega$ ) | $R_p$ (k $\Omega$ ) | $R_{CT}$ ( $\Omega$ ) | CPE ( $\mu\text{Mho}\cdot\text{s}^{\wedge\wedge}$ ) | N    | Rw (mMho $\cdot\text{s}^{1/2}$ ) | Convergence fit ( $\chi^2$ ) | Number of iterations | Convergence |
|--|--------------------|---------------------|-----------------------|---|------|----------------------------------|------------------------------|----------------------|-------------|
| $\text{C}_3\text{N}_4$ nanosheets  | 45.4               | 0.871               | 825.6                 | 3.72  | 0.74 | 1.56                             | 0.009                        | 46                   | ✓           |
| $\text{C}_3\text{N}_4/\text{RGO}$  | 53.4               | 0.759               | 705.6                 | 1.55  | 0.82 | 1.58                             | 0.158                        | 300                  | ✓           |
| $\text{C}_3\text{N}_4/\text{RGO}/\text{Chi}$ nanocomposite   | 60.5               | 0.107               | 46.5                  | 1.39  | 0.92 | 1.98                             | 0.024                        | 35                   | ✓           |
| $\text{C}_3\text{N}_4/\text{RGO}/\text{Chi}/\text{SARS-CoV-2}$ spike antigen                                 | 58.8               | 1.64                | 1581.2                | 0.76  | 0.89 | 1.55                             | 0.011                        | 33                   | ✓           |
| $\text{C}_3\text{N}_4/\text{RGO}/\text{Chi}/\text{SARS-CoV-2}$ spike antigen/BSA                             | 97.7               | 1.96                | 1862.3                | 1.46  | 0.82 | 1.20                             | 0.019                        | 39                   | ✓           |
| $\text{C}_3\text{N}_4/\text{RGO}/\text{Chi}/\text{SARS-CoV-2}$ spike antigen/BSA/SARS-CoV-2 spike antibodies | 57.3               | 2.41                | 2352.7                | 0.66  | 0.90 | 1.40                             | 0.010                        | 34                   | ✓           |

other relaxation events happened at the interface between the electrode and redox solution at frequencies lower than 10 Hz.<sup>69</sup>

The correlation between CV, DPV, and EIS data suggests that the surface modification of the working electrode

has been done. The scan rates studies of the  $\text{C}_3\text{N}_4/\text{RGO}/\text{Chi}$  nanocomposite and fabricated immunosensor show good linearity as shown in Fig. S5A and B (ESI<sup>†</sup>) respectively.



### Optimization studies for fabrication of immunosensor

The process parameters involved in the fabrication of the immunosensor were optimized using the DPV technique for higher performance and sensitivity. Initially, the volume study of  $C_3N_4$ /RGO/Chi nanocomposite was done to optimize the volume to be drop cast on the electrode for the maximum electrochemical response. As seen in Fig. 5A, the maximum DPV peak current response was observed for 4  $\mu\text{L}$ , hence 4  $\mu\text{L}$  of  $C_3N_4$ /RGO/Chi nanocomposite was selected for drop cast and further surface modifications. Further, the EDC/NHS cross-linker incubation time was optimized. As seen in Fig. 5B, the cross-linker incubation time was varied from 30–150 minutes and the maximum DPV current response was obtained for 90 minutes. Hence, 90 minutes was selected as the optimal incubation time for the cross-linker for further electrode modification. Subsequently, the varied concentration of SARS-CoV-2 spike antigen from 1 to 10  $\mu\text{g mL}^{-1}$  was optimized for the modification of the electrode surface. As seen in Fig. 5C, the maximum DPV current response was observed for 5  $\mu\text{g mL}^{-1}$ . Hence the optimal concentration of the SARS-CoV-2 spike

antigen was selected to be 5  $\mu\text{g mL}^{-1}$  for further modification. Moreover, the incubation time of the SARS-CoV-2 spike antigen plays an important role in the effective binding of the spike antigen to the surface. The incubation time study was carried out for 3–20 h. As seen from Fig. 5D, the maximum DPV current response was obtained for 12 h, hence 12 h was selected as the optimum incubation time for the SARS-CoV-2 spike antigen. At last, after the fabrication of the immunosensor, the spike antibodies incubation study was carried out to examine the antigen–antibody interaction. The SARS-CoV-2 spike antibodies were incubated for 2–50 minutes and recorded after a fixed interval. The DPV current response achieved a saturation at 45 mins and negligible signal change was observed at 50 mins. Hence, 45 mins was noted as the incubation time of the SARS-CoV-2 spike antibodies as seen in Fig. 5E.

Based on the optimization studies during the fabrication steps of the immunosensor as summarized in tabular form Fig. 5F, the optimal values were selected to evaluate the performance of the immunosensor for the detection of the SARS-CoV-2 spike antibodies.



Fig. 5 The optimization data for the fabrication of the immunosensor; (A) volume of  $C_3N_4$ /RGO/Chi nanocomposite, (B) EDC/NHS cross-linker incubation time, (C) SARS-CoV-2 spike antigen concentration, (D) SARS-CoV-2 spike antigen immobilization time, and (E) SARS-CoV-2 antibody incubation time, 0.1 M PBS (pH 7.4) containing 0.1M KCl and 5 mM ferri/ferrocyanide redox solution, (F) the summarized optimization data in tabular format.



### Detection of SARS-CoV-2 spike antibodies in PBS solution

For the detection of the SARS-CoV-2 spike antibodies using the fabricated immunosensor, the DPV technique was employed. During the analysis of SARS-CoV-2 spike antibodies in the wide concentration range of  $10 \text{ zg mL}^{-1}$  to  $100 \text{ ng mL}^{-1}$ , the current response decreases with an increase in the concentration of the SARS-CoV-2 spike antibodies. As shown in Fig. 6A, the immunosensor attained saturation at a concentration of  $100 \text{ ng mL}^{-1}$ . In addition,  $\Delta i$  values were calculated using the corresponding current values of each concentration and its difference from the response obtained for immunosensor (without analyte). The maximal current of the immunosensor (in the absence of SARS-CoV-2 spike antibodies) was  $11 \mu\text{A}$ . This was used to determine the respective  $\Delta i$  values for each concentration, which were then plotted on the calibration curve (Fig. 6B) in the range of  $10 \text{ zg mL}^{-1}$  to  $100 \text{ ng mL}^{-1}$ . The error bars in Fig. 6B represent the reproducibility of the method which was measured individually. The LOD and LOQ were calculated using the standard equations,

$$\text{LOD} = 3.3 \times \frac{\text{S.D.}}{S}; \quad (2)$$

$$\text{LOQ} = 10 \times \frac{\text{S.D.}}{S}; \quad (3)$$

where S.D. is the standard deviation, ( $\text{S.D.} = \sqrt{N} \times \text{S.E.}$ ,  $N = 14.0$ , and  $S$  is the slope of the calibration curve ( $3.52 \times 10^{-7}$ ),  $\text{S.E.} = (9.44 \times 10^{-8})$  standard error of intercept;

$\text{S.D.} = 3.53 \times 10^{-7}$ . The obtained values of LOD and LOQ are  $3.31 \text{ zg mL}^{-1}$  and  $10.03 \text{ zg mL}^{-1}$  in PBS (pH 7.4) solution respectively.

Particularly, for the detection of SARS-CoV-2 infections, few works have been reported on  $\text{C}_3\text{N}_4$ -based nanocomposites. However, this work presents the lowest detection limit among all reported studies. A comparative table of recent SARS-CoV-2 antibody electrochemical immunosensors is given in ESI† as Table S1.

### Analytical performance in spiked serum samples

After the successful detection of the SARS-CoV-2 spike antibodies in PBS (pH 7.4) solution. The performance of the immunosensor was validated in spiked serum samples *via* the DPV technique taking  $100 \text{ ag mL}^{-1}$  as the lowest detectable concentration. The current response curve is shown in Fig. 6C, where the current response decreases with an increase in the concentration of the target (SARS-CoV-2 spike antibodies) analyte. This decrease is attributed to the hindrance in electron mobility due to the addition of bulky biomolecules that restrict the transfer of electrons. The change in the current of each concentration of analyte concerning the immunosensor was calculated and plotted against the log of concentration to draw the corresponding calibration curve (Fig. 6D). From the calibration curve, the statistical analysis of the immunosensor was done to evaluate the performance in spiked serum samples. The correlation




Fig. 6 (A) Detection of SARS-CoV-2 spike antibodies *via* DPV in the concentration range of  $10 \text{ zg mL}^{-1}$  to  $100 \text{ ng mL}^{-1}$  in  $0.1 \text{ M}$  PBS (pH 7.4) containing  $0.1 \text{ M}$  KCl and  $5 \text{ mM}$  ferri/ferrocyanide redox solution, (B) corresponding calibration curve for the determination of LOD and other statistical data, (C) detection of SARS-CoV-2 spike antibodies in spiked serum samples *via* DPV in the concentration range of  $100 \text{ ag mL}^{-1}$  to  $100 \text{ ng mL}^{-1}$ , and (D) corresponding calibration curve for the determination of LOD and other statistical data.



coefficient ( $R^2$ ) value of the curve suggests significant sensitivity and favorable performance of the immunosensor. The obtained LOD and LOQ values for spiked serum samples are  $1.73 \text{ ag mL}^{-1}$  and  $5.25 \text{ ag mL}^{-1}$ , respectively. The performance of the immunosensor in PBS (pH 7.4) and spiked serum samples validates it for use in the examination of patient samples.

### Selectivity, reproducibility, and stability studies of the immunosensor

The selectivity of the immunosensor was evaluated by using various biomolecules present in biological fluids as interfering agents. Various proteins such as prostate-specific antigen (PSA) ( $100 \text{ ng mL}^{-1}$ ), immunoglobulin G (rabbit) (IgG (R)) ( $100 \text{ ng mL}^{-1}$ ), immunoglobulin G (human) (IgG (H)) ( $100 \text{ ng mL}^{-1}$ ), dopamine (DA) ( $100 \text{ ng mL}^{-1}$ ), hemoglobin (Hb) ( $100 \text{ ng mL}^{-1}$ ), and human serum albumin (HSA) ( $100 \text{ ng mL}^{-1}$ ) were used as potential interfering analytes. As seen in Fig. 7A, the immunosensor response was similar to that of the interfering analytes whereas, for the SARS-CoV-2 spike antibodies ( $10 \text{ ng mL}^{-1}$ ), the obtained current response is significantly less than the immunosensor. The change in current ( $\Delta i$ ) for SARS-CoV-2 spike antibodies and insignificant difference in  $\Delta i$  for interfering analytes suggests that the immunosensor is highly selective towards SARS-CoV-2 spike antibodies.<sup>70</sup>

Further, the stability study of the immunosensor was conducted by keeping the immunosensor at  $4^\circ \text{C}$  and evaluating its

detection capability with  $100 \text{ ng mL}^{-1}$  SARS-CoV-2 spike antibody. Results in Fig. 7B reveal that the immunosensor performs well within a week time and then gradually the performance decays in the second week. This suggests that the immunosensor is stable for a week for sensitive detection of SARS-CoV-2 spike antibodies. Moreover, the reproducibility was evaluated by constructing six different immunosensors by the same protocol. All the immunosensors were electrochemically characterized by the DPV technique and their respective peak currents were analyzed. As seen in Fig. 7C, the electrode-to-electrode standard variation of DPV peak current was calculated to be less than 5% which suggests that the fabricated immunosensors are reproducible in performance.

### Detection of SARS-CoV-2 spike antibodies in real serum samples

After the successful detection of SARS-CoV-2 spike antibodies in PBS (pH 7.4) and spiked serum samples, the performance of the immunosensor was further analyzed in real patient samples. For the initial validation of the immunosensor, 10 positive and 10 negative samples of SARS-CoV-2 infected patients were selected that were previously screened by RT-PCR and in-house ELISA kit. The samples were analyzed through DPV, and the respective current responses were recorded. For the positive samples, the current value lies between  $12\text{--}16 \mu\text{A}$ , whereas for negative samples the current values were in the range of



Fig. 7 (A) Selectivity study of the immunosensor using different interfering analytes PSA ( $100 \text{ ng mL}^{-1}$ ), IgG(R) ( $100 \text{ ng mL}^{-1}$ ), DA ( $100 \text{ ng mL}^{-1}$ ), Hb ( $100 \text{ ng mL}^{-1}$ ), HAS ( $100 \text{ ng mL}^{-1}$ ), IgG (H) ( $100 \text{ ng mL}^{-1}$ ), and  $10 \text{ ng mL}^{-1}$  of SARS-CoV-2 spike antibodies (B) stability study of the immunosensor, (C) reproducibility on six different immunosensors, and (D) electrochemical validation of the fabricated immunosensor using real COVID-19 patient serum samples. The estimated threshold for screening of positive and negative samples is  $16.5 \mu\text{A}$ .



**Table 2** The validation of the electrochemical immunosensor with standard testing methods for the detection of SARS-CoV-2 spike antibodies in real patient serum samples

| S.No. | Sample ID | SARS-CoV-2 antibodies | ELISA result | DPV current value ( $\mu\text{A}$ ) | Electrochemical Immunosensor | Validated |
|-------|-----------|-----------------------|--------------|-------------------------------------|------------------------------|-----------|
| 1.    | P1        | YES                   | +            | 16.42                               | +                            | ✓         |
| 2.    | P2        | YES                   | +            | 15.35                               | +                            | ✓         |
| 3.    | P3        | YES                   | +            | 15.33                               | +                            | ✓         |
| 4.    | P4        | YES                   | +            | 14.12                               | +                            | ✓         |
| 5.    | P5        | YES                   | +            | 14.69                               | +                            | ✓         |
| 6.    | P6        | YES                   | +            | 13.67                               | +                            | ✓         |
| 7.    | P7        | YES                   | +            | 13.67                               | +                            | ✓         |
| 8.    | P8        | YES                   | +            | 13.20                               | +                            | ✓         |
| 9.    | P9        | YES                   | +            | 12.88                               | +                            | ✓         |
| 10.   | P10       | YES                   | +            | 12.93                               | +                            | ✓         |
| 11.   | N1        | NO                    | –            | 20.15                               | –                            | ✓         |
| 12.   | N2        | NO                    | –            | 20.19                               | –                            | ✓         |
| 13.   | N3        | NO                    | –            | 20.23                               | –                            | ✓         |
| 14.   | N4        | NO                    | –            | 19.32                               | –                            | ✓         |
| 15.   | N5        | NO                    | –            | 19.02                               | –                            | ✓         |
| 16.   | N6        | NO                    | –            | 20.01                               | –                            | ✓         |
| 17.   | N7        | NO                    | –            | 16.98                               | –                            | ✓         |
| 18.   | N8        | NO                    | –            | 16.82                               | –                            | ✓         |
| 19.   | N9        | NO                    | –            | 17.10                               | –                            | ✓         |
| 20.   | N10       | NO                    | –            | 17.22                               | –                            | ✓         |

16–20  $\mu\text{A}$ . The details are included in tabular form as Table 2. The threshold was estimated according to the current response of the control (blank) sample.<sup>71</sup> The threshold for the screening of positive and negative was set at 16.5  $\mu\text{A}$ . The positive COVID-19 samples had current values of <16.5  $\mu\text{A}$ , whereas the negative had >16.5  $\mu\text{A}$ . The testing data of all positive and negative samples based on threshold values are depicted in Fig. 7D.

## Conclusion

In summary, the utilization of bio-functionalized  $\text{C}_3\text{N}_4/\text{RGO}$  nanocomposite has demonstrated promising prospects in the field of immunosensing. The inclusion of  $\text{C}_3\text{N}_4$  and RGO inside the nanocomposite offers enhanced electrical conductivity and a significantly expanded surface area, facilitating the effective binding of biomolecules. Additionally, the presence of biopolymer, Chi within the nanocomposite contributes to its biocompatibility and enhances the stability of the biomolecules that are bound to its surface ( $A_{\text{eff}} = 12 \times 10^{-2} \text{ cm}^{-2}$ ). Subsequently, bio-functionalized  $\text{C}_3\text{N}_4/\text{RGO}$  nanocomposite showed highly sensitive electrochemical immunosensing capabilities for the detection of SARS-CoV-2 spike antibodies in PBS (sensitivity = 2.9  $\mu\text{A mL zg}^{-1} \text{ cm}^{-2}$ ), spiked serum samples, and even in real patient samples. The electrochemical analysis reveals that the immunosensor performs very efficiently with an ultra-low detection limit of antibodies against the SARS-CoV-2 spike antigen and adequately differentiates between positive and negative samples. Moreover, the immunosensor also showed high selectivity, reproducibility, and high accuracy. Probable limitations of the proposed work that need to be further studied are the improvement of its stability and detection linearity. Nonetheless, the real sample results being validated by RT-PCR and ELISA techniques suggest the successful development of the immunosensor for the effective detection of

antibodies against the SARS-CoV-2 spike antigen in real samples. However, further work is needed for the standardization of the results and translation into portable immunosensors for use in POCT of COVID-19 patients.

## Author contributions

Mohd. Abubakar Sadique: conceptualization, methodology, writing – original draft preparation, validation, software, writing – reviewing and editing; Shalu Yadav: software, writing – original draft preparation, data curation, writing – reviewing and editing, validation; Pushpesh Ranjan: data curation, validation, writing – reviewing and editing; Raghuraj Singh Chouhan: methodology, data curation, writing – reviewing and editing, software, validation; Ivan Jerman: writing – reviewing and editing, validation; Ashok Kumar: visualization, investigation, validation, writing – reviewing and editing; Saurabh Saigal: validation, writing – reviewing and editing; Sagar Khadanga: writing – reviewing and editing, validation; and Raju Khan: conceptualization, reviewing and editing, validation, supervision.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

The authors would like to thank the Director, Council of Scientific and Industrial Research (CSIR)-AMPRI, Bhopal for his encouragement for this work. M.A.S. is obliged to the Science and Engineering Research Board (SERB) for JRF. R.K. would like to acknowledge SERB and CSIR for financial aid for this work under the project IPA/2020/000130 and MLP-0301, respectively. S. Y. and P. R. are thankful to the CSIR for providing the SRF. The authors would express gratitude to CSIR-AMPRI for materials



characterization facilities. The Slovenian Research Agency is acknowledged through the funding of projects ARRS N1-0100, J1-1716, P2-0393, BI-US/22-24-162, IsoCont J1-3033, and program P1-0143.

## References

- 1 A. L. Lorenzen, A. M. dos Santos, L. P. dos Santos, L. da Silva Pinto, F. R. Conceição and F. Wolfart, *Electrochim. Acta*, 2022, **404**, 139757.
- 2 B. Udugama, P. Kadhiresan, H. N. Kozłowski, A. Malekjahani, M. Osborne, V. Y. C. Li, H. Chen, S. Mubareka, J. B. Gubbay and W. C. W. Chan, *ACS Nano*, 2020, **14**, 3822–3835.
- 3 G. Alhamid, H. Tombuloglu, A. A. Rabaan and E. Al-Suhaimi, *Saudi J. Biol. Sci.*, 2022, **29**, 103465.
- 4 Y. P. Chong, K. W. Choy, C. Doerig and C. X. Lim, *Mol. Diagn. Ther.*, 2023, **27**, 303–320.
- 5 L. J. Carter, L. v Garner, J. W. Smoot, Y. Li, Q. Zhou, C. J. Saveson, J. M. Sasso, A. C. Gregg, D. J. Soares, T. R. Beskid, S. R. Jervey and C. Liu, *ACS Cent. Sci.*, 2020, **6**, 591–605.
- 6 J. Guo, J. Ge and Y. Guo, *J. Clin. Lab. Anal.*, 2022, **36**, e24178.
- 7 M. A. Sadique, S. Yadav, P. Ranjan, S. Verma, S. T. Salammal, M. A. Khan, A. Kaushik and R. Khan, *J. Mater. Chem. B*, 2021, **9**, 4620–4642.
- 8 A. Parihar, S. Yadav, M. A. Sadique, P. Ranjan, N. Kumar, A. Singhal, V. Khare, R. Khan, S. Natarajan and A. K. Srivastava, *Bioeng. Transl. Med.*, 2023, e10481.
- 9 D. Namdeo, A. K. Singh, A. Meher, A. K. Yadav and D. Biswas, COVID-19 diagnosis: approaches and challenges, in *Advanced Biosensors for Virus Detection*, ed. R. Khan, A. Parihar, A. Kaushik and A. Kumar, Academic Press, 2022, pp. 61–77.
- 10 L. Tessaro, A. Aquino, A. C. de Morais Mirres and C. A. Conte-Junior, Nanotechnology advancements in antiviral coatings to combat viral infection surfaces, in *Smart Nanomaterials to Combat the Spread of Viral Infections*, ed. R. Khan and M. A. Sadique, Elsevier, 2023, pp. 125–146.
- 11 S. Yadav, A. Parihar, M. A. Sadique, P. Ranjan, N. Kumar, A. Singhal and R. Khan, *ACS Appl. Opt. Mater.*, 2023, **1**(7), 1245–1262.
- 12 G. Simone, *ArXiv*, 2020, 1–8.
- 13 C. Wang, X. Yang, B. Gu, H. Liu, Z. Zhou, L. Shi, X. Cheng and S. Wang, *Anal. Chem.*, 2020, **92**, 15542–15549.
- 14 P. E. Guevara-Pantoja, R. Rodriguez-Moncayo, O. G. Chavez-Pineda, D. F. Cedillo-Alcantar, K. B. Reynoso-Hernandez, J. A. Ramirez-Pool, L. A. Nuñez-Muñoz, B. Xocnostle-Cazares and J. L. Garcia-Cordero, *Adv. Mater. Technol.*, 2023, **8**, 2200902.
- 15 D. Mandal, M. M. Indaleeb, A. Younan and S. Banerjee, *Sens. Biosensing Res.*, 2022, **37**, 100510.
- 16 P. Fathi-Hafshejani, N. Azam, L. Wang, M. A. Kuroda, M. C. Hamilton, S. Hasim and M. Mahjouri-Samani, *ACS Nano*, 2021, **15**, 11461–11469.
- 17 B. A. Braz, M. Hospinal-Santiani, G. Martins, J. L. Gogola, M. G. P. Valenga, B. C. B. Beirão, M. F. Bergamini, L. H. Marcolino-Junior, V. Thomaz-Soccol and C. R. Soccol, *Talanta*, 2023, **257**, 124348.
- 18 B. Della Ventura, M. Cennamo, A. Minopoli, R. Campanile, S. B. Censi, D. Terracciano, G. Portella and R. Velotta, *ACS Sens.*, 2020, **5**, 3043–3048.
- 19 C. Mann, J. S. Hoyle and K. M. Downard, *Analyst*, 2022, **147**, 1181–1190.
- 20 M. A. Sadique, P. Ranjan, S. Yadav and R. Khan, Advanced high-throughput biosensor-based diagnostic approaches for detection of severe acute respiratory syndrome-coronavirus-2, *Computational Approaches for Novel Therapeutic and Diagnostic Designing to Mitigate SARS-CoV2 Infection*, Academic Press, 2022, pp. 147–169.
- 21 R. Kour, S. Arya, S.-J. Young, V. Gupta, P. Bandhoria and A. Khosla, *J. Electrochem. Soc.*, 2020, **167**, 37555.
- 22 K. Kerman, M. Saito, E. Tamiya, S. Yamamura and Y. Takamura, *TrAC, Trends Anal. Chem.*, 2008, **27**, 585–592.
- 23 S. Yadav, M. A. Sadique, A. Kaushik, P. Ranjan, R. Khan and A. K. Srivastava, *J. Mater. Chem. B*, 2022, **10**, 1146–1175.
- 24 M. Abubakar Sadique, S. Yadav, P. Ranjan, M. Akram Khan, A. Kumar and R. Khan, *Mater. Lett.*, 2021, **305**, 130824.
- 25 W. Zhang, Y. Qin, W. Wang, F. Liu, F. Meng, F. Chen, N. Zhu, A. Aihaiti and M. Zhang, *Electrochim. Acta*, 2021, **391**, 138970.
- 26 M. A. Sadique, S. Yadav, P. Ranjan, R. Khan, F. Khan, A. Kumar and D. Biswas, *ACS Appl. Bio. Mater.*, 2022, **5**, 2421–2430.
- 27 S. Yadav, M. A. Sadique, P. Ranjan, R. Khan, N. Sathish and A. K. Srivastava, *J. Mater. Chem. B*, 2022, **10**(41), 8478–8489.
- 28 M. Sadique, S. Yadav, V. Khare, R. Khan, G. K. Tripathi and P. S. Khare, *Diagnostics*, 2022, **12**.
- 29 M. A. Kachouei, F. Hekmat, H. Wang, G. A. J. Amaratunga, H. E. Unalan and S. Shahrokhian, *Electrochim. Acta*, 2022, **428**, 140952.
- 30 P. Ranjan, M. Abubakar Sadique, S. Yadav and R. Khan, *ACS Appl. Mater. Interfaces*, 2022, **14**, 20802–20812.
- 31 Y. Wang, J. Ma, X. Ye, W. Wong, C. Li and K. Wu, *Electrochim. Acta*, 2018, **271**, 551–559.
- 32 P. Ranjan, S. Yadav, M. A. Sadique, R. Khan and A. K. Srivastava, *ACS Appl. Nano Mater.*, 2022, **5**, 14999–15010.
- 33 A. O. Idris, E. O. Oseghe, T. A. M. Msagati, A. T. Kuvarega, U. Feleni and B. Mamba, *Sensors*, 2020, **20**, 1–28.
- 34 Q. Hong, H. Yang, Y. Fang, W. Li, C. Zhu, Z. Wang, S. Liang, X. Cao, Z. Zhou, Y. Shen, S. Liu and Y. Zhang, *Nat. Commun.*, 2023, **14**, 2780.
- 35 Y. Hou, Y. Fang, Z. Zhou, Q. Hong, W. Li, H. Yang, K. Wu, Y. Xu, X. Cao, D. Han, S. Liu, Y. Shen and Y. Zhang, *Adv. Opt. Mater.*, 2023, **11**, 2202737.
- 36 Y. Fang, Z. Zhou, Y. Hou, C. Wang, X. Cao, S. Liu, Y. Shen and Y. Zhang, *Anal. Chem.*, 2023, **95**, 6620–6628.
- 37 R. Chouhan, J. Gačnik and M. Horvat, in EGU General Assembly Conference Abstracts, AA(Jožef Stefan Institute, Department of Environmental Sciences, Slovenia), AB(Jožef Stefan Institute, Department of Environmental Sciences, Slovenia), AC(Jožef Stefan Institute, Department of Environmental Sciences, Slovenia), 2022, pp. EGU22–8308.
- 38 L. G. da S. Catunda, T. Martimiano do Prado, T. R. de Oliveira, D. J. Almeida dos Santos, N. O. Gomes, D. S. Correa, R. C. Faria and S. A. S. Machado, *Electrochim. Acta*, 2023, **451**, 142271.



- 39 A. V. Police Patil, Y.-S. Chuang, C. Li and C.-C. Wu, *Biosensors*, 2023, **13**, 125.
- 40 N. Singh, D. S. Dkhar, P. Chandra and U. P. Azad, *Biosensors*, 2023, **13**, 166.
- 41 A. Koyappayil, A. K. Yagati and M. H. Lee, *Biosensors*, 2023, **13**, 91.
- 42 R. S. Chouhan, I. Jerman, D. Heath, S. Bohm, S. Gandhi, V. Sadhu, S. Baker and M. Horvat, *Nano Select*, 2021, **2**, 712–743.
- 43 Q. Cao, B. Kumru, M. Antonietti and B. V. K. J. Schmidt, *Mater. Horiz.*, 2020, **7**, 762–786.
- 44 C. Zhao, Q. Yan, S. Wang, P. Dong and L. Zhang, *RSC Adv.*, 2018, **8**, 27516–27524.
- 45 S. Amirthalingam and J. Rangasamy, in *Advances in Polymer Science*, ed. R. Jayakumar and M. Prabakaran, Springer International Publishing, Cham, 2021, vol. 287, pp. 233–255.
- 46 W. Suginta, P. Khunkaewla and A. Schulte, *Chem. Rev.*, 2013, **113**, 5458–5479.
- 47 Y. Jiang and J. Wu, *Electrophoresis*, 2019, **40**, 2084–2097.
- 48 M. Amouzadeh Tabrizi, L. Nazari and P. Acedo, *Sens. Actuators, B*, 2021, **345**, 130377.
- 49 T. Yin, Y. Ye, W. Dong and G. Jie, *Biosens. Bioelectron.*, 2022, **215**, 114580.
- 50 C. N. Botelho, S. S. Falcão, R.-E. P. Soares, S. R. Pereira, A. S. de Menezes, L. T. Kubota, F. S. Damos and R. C. S. Luz, *Biosens. Bioelectron X*, 2022, **11**, 100167.
- 51 C. Karaman, B. B. Yola, O. Karaman, N. Atar, İ. Polat and M. L. Yola, *Mikrochim. Acta*, 2021, **188**, 425.
- 52 R. S. Chouhan, G. Žitko, V. Fajon, I. Živković, M. Pavlin, S. Berisha, I. Jerman, A. Vesel and M. Horvat, *Sensors*, 2019, **19**, 3432.
- 53 D. C. Marcano, D. v Kosynkin, J. M. Berlin, A. Sinitskii, Z. Sun, A. S. Slesarev, L. B. Alemany, W. Lu and J. M. Tour, *ACS Nano*, 2018, **12**, 2078.
- 54 J. Wang, B. Yang, S. Li, B. Yan, H. Xu, K. Zhang, Y. Shi, C. Zhai and Y. Du, *J. Colloid Interface Sci.*, 2017, **506**, 329–337.
- 55 C. Guo, C. Wang, H. Sun, D. Dai and H. Gao, *RSC Adv.*, 2021, **11**, 29590–29597.
- 56 R. Maharsi, A. F. Arif, T. Ogi, H. Widiyandari and F. Iskandar, *RSC Adv.*, 2019, **9**, 27896–27903.
- 57 I. O. Faniyi, O. Fasakin, B. Olofinjana, A. S. Adekunle, T. V. Oluwasusi, M. A. Eleruja and E. O. B. Ajayi, *SN Appl. Sci.*, 2019, **1**, 1181.
- 58 N. Sharma, R. Vyas, V. Sharma, H. Rahman, S. K. Sharma and K. Sachdev, *Appl. Nanosci.*, 2020, **10**, 517–528.
- 59 M. Ruidíaz-Martínez, M. A. Álvarez, M. V. López-Ramón, G. Cruz-Quesada, J. Rivera-Utrilla and M. Sánchez-Polo, *Catalysts*, 2020, **10**, 520.
- 60 H. Zhang, L. Peng, A. Chen, C. Shang, M. Lei, K. He, S. Luo, J. Shao and Q. Zeng, *Carbohydr. Polym.*, 2019, **214**, 276–285.
- 61 S. Anicuta, L. Dobre, M. Stroescu and I. Jipa, Analele Universitatii din Oradea Fascicula: Ecotoxicologie, Zootehnie si Tehnologii de Industrie Alimentara, 2010, 1234–1240.
- 62 Y. Fu, J. Zhu, C. Hu, X. Wu and X. Wang, *Nanoscale*, 2014, **6**, 12555–12564.
- 63 S. Zhang, N. T. Hang, Z. Zhang, H. Yue and W. Yang, *Nanomaterials*, 2017, **7**, 1–11.
- 64 C. C. Ryan, M. Bardosova and M. E. Pemble, *J. Mater. Sci.*, 2017, **52**, 8338–8347.
- 65 D. Adekoya, M. Li, M. Hankel, C. Lai, M. S. Balogun, Y. Tong and S. Zhang, *Energy Storage Mater.*, 2020, **25**, 495–501.
- 66 M. Azmana, S. Mahmood, A. R. Hilles, A. Rahman, M. A. Bin Arifin and S. Ahmed, *Int. J. Biol. Macromol.*, 2021, **185**, 832–848.
- 67 S. Yadav, M. A. Sadique, P. Ranjan and R. Khan, *Anal. Chim. Acta*, 2023, 341326.
- 68 B. P. Charitha and P. Rao, *Int. J. Biol. Macromol.*, 2018, **112**, 461–472.
- 69 D. Debnath, S. H. Kim and K. E. Geckeler, *J. Mater. Chem.*, 2009, **19**, 8810–8816.
- 70 J. Zhao, Z. Fu, H. Li, Y. Xiong, S. Cai, C. Wang, Y. Chen, N. Han and R. Yang, *Electrochim. Acta*, 2022, **404**, 139766.
- 71 D. Najjar, J. Rainbow, S. Sharma Timilsina, P. Jolly, H. De Puig, M. Yafia, N. Durr, H. Sallum, G. Alter, J. Z. Li, X. G. Yu, D. R. Walt, J. A. Paradiso, P. Estrela, J. J. Collins and D. E. Ingber, *Nat. Biomed. Eng.*, 2022, **6**, 968–978.

